Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement.

[1]  R. Gelber,et al.  Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. , 2023, The New England journal of medicine.

[2]  Yang Luo,et al.  Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node–Positive Breast Cancer , 2023, JAMA network open.

[3]  M. Piccart,et al.  Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer. , 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  P. Neven,et al.  Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. , 2022, The Lancet. Oncology.

[5]  S. Loi,et al.  Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice , 2022, Nature Cancer.

[6]  W. Wallace,et al.  Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy. , 2022, European journal of cancer.

[7]  R. Rosario,et al.  Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies , 2022, Reproduction & fertility.

[8]  C. Denkert,et al.  60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B , 2022, Annals of Oncology.

[9]  Richard A. Anderson,et al.  Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials , 2022, Breast.

[10]  F. Puglisi,et al.  Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review , 2021, ESMO open.

[11]  R. Houot,et al.  Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Winer,et al.  Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial) , 2021, Breast Cancer Research and Treatment.

[13]  P. Fasching,et al.  Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials. , 2021, European journal of cancer.

[14]  S. Loi,et al.  Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation. , 2021, Journal of the National Cancer Institute.

[15]  Y. Jung,et al.  Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report. , 2021, European journal of cancer.

[16]  David Handelsman,et al.  Oncofertility Information Available for Recently Approved Novel Non Cytotoxic and Immunotherapy Oncology Drugs , 2021, Clinical pharmacology and therapeutics.

[17]  A. Giwercman,et al.  Premature ovarian failure after childhood cancer and risk of metabolic syndrome - a cross-sectional analysis. , 2021, European journal of endocrinology.

[18]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[19]  C. Isaacs,et al.  Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function , 2021, Breast Cancer Research and Treatment.

[20]  N. Suzuki,et al.  Poly (ADP-ribose) polymerase inhibitor exposure reduces ovarian reserve followed by dysfunction in granulosa cells , 2020, Scientific Reports.

[21]  F. Amant,et al.  ESHRE guideline: female fertility preservation† , 2020, Human reproduction open.

[22]  F. Amant,et al.  Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  K. Phillips,et al.  The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation. , 2020, Human reproduction.

[24]  S. Ingles,et al.  Long-term imatinib diminishes ovarian reserve and impacts embryo quality , 2020, Journal of Assisted Reproduction and Genetics.

[25]  R. Garje,et al.  Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence , 2020, Cancers.

[26]  M. De Felici,et al.  Ovarian damage from chemotherapy and current approaches to its protection , 2019, Human reproduction update.

[27]  A. Goldhirsch,et al.  Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers. , 2019, Breast.

[28]  C. Bowman,et al.  Reproductive and Developmental Toxicity Assessment of Palbociclib, a CDK4/6 Inhibitor, in Sprague-Dawley Rats and New Zealand White Rabbits. , 2019, Reproductive toxicology.

[29]  J. Forbes,et al.  Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. , 2018, Journal of the National Cancer Institute.

[30]  N. Kalakonda,et al.  Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial , 2018, The Lancet. Oncology.

[31]  R. Gelber,et al.  Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients , 2018, Journal of the National Cancer Institute.

[32]  S. Loibl,et al.  Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  K. Oktay,et al.  Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Ignatiadis,et al.  Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. , 2018, Journal of the National Cancer Institute.

[35]  G. Armstrong,et al.  Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study , 2018, Cancer.

[36]  J. Ferlay,et al.  Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study. , 2017, The Lancet. Oncology.

[37]  W. Barry,et al.  Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis , 2017, JAMA oncology.

[38]  F. Peccatori,et al.  Mechanisms of chemotherapy-induced ovarian damage in breast cancer patients. , 2017, Critical reviews in oncology/hematology.

[39]  M. H. van den Berg,et al.  Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: A systematic review. , 2017, Cancer treatment reviews.

[40]  T. Almeida-Santos,et al.  Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis. , 2016, Human reproduction.

[41]  Kayla L. Stratton,et al.  Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort. , 2016, The Lancet. Oncology.

[42]  R. Cífková,et al.  ESHRE Guideline: management of women with premature ovarian insufficiency. , 2016, Human Reproduction.

[43]  A. Mertens,et al.  Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all. , 2016, Fertility and sterility.

[44]  S. Iliodromiti,et al.  Technical and performance characteristics of anti-Müllerian hormone and antral follicle count as biomarkers of ovarian response. , 2015, Human reproduction update.

[45]  W. Rocca,et al.  Long-term health consequences of premature or early menopause and considerations for management , 2015, Climacteric : the journal of the International Menopause Society.

[46]  M. Ellis,et al.  Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial) , 2015, Breast Cancer Research and Treatment.

[47]  C. E. Dunlop,et al.  Uses of anti-Müllerian hormone (AMH) measurement before and after cancer treatment in women. , 2015, Maturitas.

[48]  J. Chai,et al.  A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer , 2014, European journal of cancer.

[49]  R. Tamimi,et al.  Prospective study of fertility concerns and preservation strategies in young women with breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  N. Raine-Fenning,et al.  Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. , 2013, Molecular human reproduction.

[51]  C. McCulloch,et al.  Acute ovarian failure underestimates age‐specific reproductive impairment for young women undergoing chemotherapy for cancer , 2012, Cancer.

[52]  Thomas W. Kelsey,et al.  Human Ovarian Reserve from Conception to the Menopause , 2009, PloS one.

[53]  E. Winer,et al.  Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. , 2007, European journal of cancer.

[54]  S. Loi,et al.  Selection of endpoints in breast cancer clinical trials: a qualitative study of key trial stakeholders. , 2022, American journal of cancer research.

[55]  OUP accepted manuscript , 2022, Human Reproduction Update.

[56]  D. Wechsler,et al.  Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.